Finucane Anne A. 4

What Happened

• Anne A. Finucane, a director of CVS Health Corp (CVS), was granted 1,544.004 deferred stock units on 2026-05-14 at a reported market value of $97.15 per share, for a total value of $150,000. The filing reports this as an award/acquisition (derivative) under the company’s director compensation arrangements.
• This was not an open‑market purchase or sale by the director but a compensation-related award (routine grant of deferred units), so it’s primarily a pay event rather than a direct bullish or bearish trading signal.

Key Details

• Transaction date: 2026-05-14; Filing date: 2026-05-15 (timely filing).
• Security: Deferred stock units (derivative), 1,544.004 units at $97.15 each; total reported value $150,000.
• Transaction code: A (award/grant/acquisition).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes: F1 — units represent deferred stock issued for deferral of a semi‑annual non‑employee director retainer pursuant to the 2017 Incentive Compensation Plan. F2 — each deferred stock unit is to be converted into one share of common stock and issued in the future as elected by the reporting person.

Context

• Deferred stock units are a form of compensation that will convert into actual shares later (as elected), so this is a derivative award rather than an immediate purchase or sale. Such grants are common for non‑employee directors and reflect standard compensation practices rather than an overt trading decision.